Novotech Boosts US Presence with NCGS Buy
Asia-Pacific contract research organization (CRO) Novotech has acquired NCGS, a US CRO with about 300 employees and a biopharma client base. Financial terms of the transaction were not disclosed. “This is a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in Asia-Pacific and the US, and for our Asia-Pacific clients wanting US clinical program, said Novotech CEO John Moller.
Based in Charleston, South Carolina, NCGS focuses on complex areas of clinical development such as oncology, hematology, infectious disease and central nervous system disorders in adult and children. Nancy Snowden, founder and CEO of NCGS added that the two companies have a longstanding history of collaboration over more than a decade, which will support a seamless integration.
In October 2020, Novotech and Asian CRO PPC Group, both owned by private equity firm TPG Capital Asia, merged to form Novotech Health Holdings in order to provide a scalable platform to serve Asia’s rapidly growing demand for clinical trial services.
Novotech said the merger makes it the largest biotech specialist CRO in Asia that can deliver full clinical services, from first-in-human to phase IV studies. Novotech Holdings employs about 1,550 people across Greater China, South Korea, southeast Asia, India and Australia/New Zealand.
Author: Elaine Burridge, Freelance Journalist
